U.S. Blood Cancer Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Blood Cancer Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask a question about the blood cancer diagnostics market
U.S. blood cancer diagnostics market highlights
- The U.S. blood cancer diagnostics market generated a revenue of USD 3,347.8 million in 2024 and is expected to reach USD 4,617.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.5% from 2025 to 2030.
- In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
- Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Blood cancer diagnostics market data book summary
| Market revenue in 2024 | USD 3,347.8 million |
| Market revenue in 2030 | USD 4,617.0 million |
| Growth rate | 5.5% (CAGR from 2025 to 2030) |
| Largest segment | Assay kits and reagents |
| Fastest growing segment | Assay Kits and Reagents |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Assay Kits and Reagents |
Other key industry trends
- In terms of revenue, U.S. accounted for 30.9% of the global blood cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. blood cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 769.6 million by 2030.
In the U.S., blood cancer is the most prevalent form of cancer. According to recent statistics from the American Cancer Society, it was estimated that over 186,000 new cases of blood cancer were to be diagnosed in 2023 in the U.S.
This staggering number highlighted the significant burden of these malignancies on the country’s healthcare system and the critical need for effective diagnostic tools & treatment modalities. The high prevalence of blood cancer in the U.S. can be attributed to several factors, including an aging population, environmental exposures, and genetic predispositions.
In addition, advancements in diagnostic techniques have led to early detection and improved reporting of these cancers. Regardless of the underlying causes, the pervasiveness of blood cancer presents a formidable challenge for healthcare providers, researchers, and policymakers, necessitating a concerted effort to develop innovative strategies for prevention, early detection, & personalized treatment approaches.
No credit card required*
Publish Date: Mar 21, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood Cancer Diagnostics Market Scope
Blood Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Bio-Techne Corp | View profile | 3,050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | www.bio-techne.com |
| Sophia Genetics SA | View profile | 449 | La Pièce 12, Rolle, Switzerland, CH-1180 | www.sophiagenetics.com |
| Adaptive Biotechnologies | View profile | 501-1000 | Seattle, Washington, United States, North America | adaptivebiotech.com |
| Danaher Corporation | View profile | - | - | - |
| QIAGEN | View profile | - | - | - |
| Abbott | View profile | - | - | - |
| Invivoscribe, Inc. | View profile | 251-500 | San Diego, California, United States, North America | www.invivoscribe.com |
U.S. Blood Cancer Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Blood Cancer Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Assay Kits And Reagents was the largest segment with a revenue share of 72.31% in 2024.
Horizon Databook has segmented the U.S. blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.
In the U.S., blood cancer is the most prevalent form of cancer. According to recent statistics from the American Cancer Society, it was estimated that over 186,000 new cases of blood cancer were to be diagnosed in 2023 in the U.S.
This staggering number highlighted the significant burden of these malignancies on the country’s healthcare system and the critical need for effective diagnostic tools & treatment modalities. The high prevalence of blood cancer in the U.S. can be attributed to several factors, including an aging population, environmental exposures, and genetic predispositions.
In addition, advancements in diagnostic techniques have led to early detection and improved reporting of these cancers. Regardless of the underlying causes, the pervasiveness of blood cancer presents a formidable challenge for healthcare providers, researchers, and policymakers, necessitating a concerted effort to develop innovative strategies for prevention, early detection, & personalized treatment approaches.
- U.S. Blood Cancer Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
- Instruments
- Assay Kits and Reagents
- U.S. Blood Cancer Diagnostics Market Test Outlook (Revenue, USD Million , 2018-2030)
- Blood Tests
- Imaging Tests
- Biopsy
- Molecular Test
- U.S. Blood Cancer Diagnostics Market Enduse Outlook (Revenue, USD Million , 2018-2030)
- Hospitals and Clinics
- Diagnostic Labs
- Research Institutes
Reasons to subscribe to Blood Cancer Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Blood Cancer Diagnostics Market Outlook databook
- Our clientele includes a mix of Blood Cancer Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Blood Cancer Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Blood Cancer Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Blood Cancer Diagnostics Market, 2018-2030 (US$M)
U.S. blood cancer diagnostics market statistics, by product, 2018-2030 (US$M)
